The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
View/ Open
Published Version
https://doi.org/10.1371/journal.pmed.1001955Metadata
Show full item recordCitation
Sarpatwari, Ameet, and Aaron S. Kesselheim. 2016. “The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?” PLoS Medicine 13 (2): e1001955. doi:10.1371/journal.pmed.1001955. http://dx.doi.org/10.1371/journal.pmed.1001955.Abstract
Ameet Sarpatwari and Aaron Kesselheim explore whether stripping branded drugs of trademark protection would improve the efficiency and fairness of health care.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747525/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658549
Collections
- HMS Scholarly Articles [17917]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)